Corrigendum

Corrigendum to “MicroRNAs as lung cancer biomarkers and key players in lung carcinogenesis” Clinical Biochemistry 46 (2013) 918–925

Ivan Vanninia,1, Francesca Faninia,b,1, Muller Fabbria,c,d,⁎

a IRCCS Istituto Scientifico Romagnolo per lo Studio e la Curia dei Tumori (I.R.S.T.) S.r.l., Meldola 47014, FC, Italy
b Istituto Oncologico Romagnolo Coop. Soc. ONLUS, Forlì 47121, FC, Italy
c Department of Pediatrics, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Saban Research Institute, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, CA 90027, USA
d Department of Molecular Microbiology and Immunology, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Saban Research Institute, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, CA 90027, USA

The authors would like to apologise for not citing a relevant paper in their review. The reference is:

Here are some specific sections of the published review which should be adapted to include this extra reference:

Weiss et al. [34] showed that EGFR was directly targeted by miR-128b and miR-128b loss-of-heterozygosity, which is frequently found in NSCLC, and positively correlated with clinical response and survival following treatment with the tyrosine kinase inhibitor (TKI) gefitinib. Moreover, Cho et al. demonstrated that miR-145 inhibited lung cancer cell growth in patients with EGFR-activating mutations [35, 55].

To conclude, TRAIL (Apo2L/tumor necrosis factor [TNF]-related apoptosis-inducing ligand) is a member of the TNF family that can induce apoptosis in several types of cancers, including lung cancer [37, 55].

Garofalo et al. [38] demonstrated the involvement of miR-221 and miR-222 to lung cancer resistance to TRAIL, by silencing PTEN and TIMP3 tumor-suppressors, emphasizing how these two miRNAs could act as biomarkers predictive of lung cancer response to a treatment with TRAIL [55].

Once again, the authors would like to apologise to the readers for any confusion this unintentional omission might have caused.

DOI of original article: https://doi.org/10.1016/j.clinbiochem.2013.01.024

⁎ Corresponding author at: Children’s Hospital Los Angeles, Division of Hematology/Oncology, 4650 Sunset Blvd, Mailstop 57, Los Angeles, CA 90027, USA.
E-mail address: mfabbri@cchawaii.edu (M. Fabbri).

1 These authors contributed equally to this work.
2 Current address of author at time of publishing this Corrigendum is: Cancer Biology Program, University of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, HI 96813, USA.

https://doi.org/10.1016/j.clinbiochem.2019.05.004

Available online 23 May 2019

© 2019 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.